Please note that we have stopped the regular imports of Gene Expression Omnibus (GEO) data into ArrayExpress. This may not be the latest version of this experiment.
E-GEOD-20181 - Letrozole (Femara) early and late responses to treatment
Released on 28 July 2010, last updated on 7 August 2015
In the present investigation, we have exploited the opportunity provided by neoadjuvant treatment of a group of postmenopausal women with large operable or locally advanced breast cancer (in which therapy is given with the primary tumour remaining within the breast) to take sequential biopsies of the same cancers before and after 10-14 days or 90 days treatment with letrozole. RNA extracted from the biopsies has been subjected to Affymetrix microarray analysis and the data from paired biopsies interrogated to discover genes whose expression is most influenced by oestrogen deprivation. Keywords: Timecourse between subjects Biopsies were taken from the same subjects at three timepoints: pretreatment, after 10-14 days Letrozol (2.5 mg/day, oral), and after 90 days Letrozol (2.5 mg/day, oral).
transcription profiling by array
Alexey Larionov, Andreas Krause, Dean B Evans, Garret Hampton, J M Dixon, John R Walker, Lorna Renshaw, Sharon White, Steven Ho, Thomas J Anderson, William R Miller
Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM.